Introduction
This analysis examines the current position and future outlook for King in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
- Benchmark Kings performance against key rivals in the ethical pharmaceutical sector
- Evaluate the impact of Kings recent divestment of its womens health business
- Understand the key drivers and resistors of Kings growth to 2010
| 
View Cart
